Effects of bacteria-mediated reprogramming and antibiotic pretreatment on the course of colitis in mice

Molecular Medicine Reports

Volumn 10, Issue 2, 2014, Pages 983-988

  Gardlik, Roman ^a   Wagnerova, Alexandra ^a   Celec, Peter ^a,b  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b Physics and Informatics   (Slovakia)

Author keywords

Antibiotics; Bacterial vectors; Colitis; Gene delivery; Preventive treatment; Reprogramming

Indexed keywords

BACTERIAL VECTOR; DEXTRAN SULFATE; DRINKING WATER; KRUPPEL LIKE FACTOR 4; METRONIDAZOLE; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; STREPTOMYCIN; TRANSCRIPTION FACTOR SOX2; ANTIINFECTIVE AGENT; KRUPPEL LIKE FACTOR; TRANSCRIPTION FACTOR SOX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; FECES; FEEDING; MALE; MOUSE; NONHUMAN; SALMONELLA TYPHIMURIUM; WEIGHT REDUCTION; ANIMAL; BACTERIA; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE THERAPY; GENE VECTOR; GENETICS; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; NUCLEAR REPROGRAMMING; ORAL DRUG ADMINISTRATION; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; TOXICITY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; CELLULAR REPROGRAMMING; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; INTESTINAL MUCOSA; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; METRONIDAZOLE; MICE; MICE, INBRED C57BL; OCTAMER TRANSCRIPTION FACTOR-3; SALMONELLA TYPHIMURIUM; SOXB1 TRANSCRIPTION FACTORS; STREPTOMYCIN; WEIGHT LOSS;

EID: 84903266584     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2244     Document Type: Article

References (21)

1. Triantafillidis JK, Merikas E and Georgopoulos F: Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 5: 185-210, 2011.
2. Blonski W, Buchner AM and Lichtenstein GR: Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 27: 346-357, 2011.
3. Thompson-Chagoyán OC, Maldonado J and Gil A: Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr 24: 339-352, 2005. (Pubitemid 40668419)
4. Matsumoto S, Hara T, Hori T, et al: Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 140: 417-426, 2005. (Pubitemid 40813951)
5. Steidler L, Hans W, Schotte L, et al: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352-1355, 2000. (Pubitemid 30656052)
6. Bibiloni R, Fedorak RN, Tannock GW, et al: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100: 1539-1546, 2005. (Pubitemid 41032360)
7. Pálffy R, Behuliak M, Gardlík R, Jáni P, Kádasi L, Turna J and Celec P: Oral in vivo bactofection in dextran sulfate sodium treated female Wistar rats. Folia Biol (Krakow) 58: 171-176, 2010.
8. Palffy R, Gardlik R, Behuliak M, et al: Salmonella-mediated gene therapy in experimental colitis in mice. Exp Biol Med (Maywood) 236: 177-183, 2011.
9. Gardlik R, Bartonova A and Celec P: Therapeutic DNA vaccination and RNA interference in inflammatory bowel disease. Int J Mol Med 32: 492-496, 2013.
10. Drouet M, Vignal C, Singer E et al: AIEC colonization and pathogenicity: influence of previous antibiotic treatment and preexisting inflammation. Inflamm Bowel Dis 18: 1923-1931, 2012.
11. Garrido-Mesa N, Utrilla P, Comalada M et al: The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. Biochem Pharmacol 82: 1891-1900, 2011.
12. Khalil PN, Weiler V, Nelson PJ et al: Nonmyeloablative stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease. Gastroenterology 132: 944-954, 2007. (Pubitemid 46440862)
13. González MA, Gonzalez-Rey E, Rico L, Büscher D and Delgado M: Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136: 978-989, 2009.
14. Zhou Q, Price DD, Dreher KL, Pronold B, Callam CS, Sharma J and Verne GN: Localized colonic stem cell transplantation enhances tissue regeneration in murine colitis. J Cell Mol Med 16: 1900-1915, 2012.
15. Wagnerova A and Gardlik R: In vivo reprogramming in inflammatory bowel disease. Gene Ther 20: 1111-1118, 2013.
16. Gardlik R: Inducing pluripotency using in vivo gene therapy. Med Hypotheses 79: 197-201, 2012.
17. Sheng X, Reppel M, Nguemo F, Mohammad FI, Kuzmenkin A, Hescheler J and Pfannkuche K: Human pluripotent stem cell-derived cardiomyocytes: response to TTX and lidocain reveals strong cell to cell variability. PLoS One 7: e45963, 2012.
18. Yamada S, Nelson TJ, Behfar A, Crespo-Diaz RJ, Fraidenraich D and Terzic A: Stem cell transplant into preimplantation embryo yields myocardial infarction-resistant adult phenotype. Stem Cells 27: 1697-1705, 2009.
19. Finkbeiner SR and Spence JR: A gutsy task: generating intestinal tissue from human pluripotent stem cells. Dig Dis Sci 58: 1176-1184, 2013.
20. Spence JR, Mayhew CN, Rankin SA, et al: Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 470: 105-109, 2011.
21. Stecher B, Denzler R, Maier L, et al: Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. Proc Natl Acad Sci USA 109: 1269-1274, 2012.